Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published

Asmaa Samy1, Mehmet Kemal Ozdemir2, Reda Alhajj3,4,5

  • 1The Graduate School of Engineering and Natural Science, Istanbul Medipol University, Istanbul, Turkey.

Scientific Reports
|February 15, 2023
PubMed

Insights

Splicing Factor 3B subunit 1 (SF3B1) mutations are linked to cancer. This study found SF3B1 is more associated with hematologic malignancies like MDS, AML, and CLL than breast cancer, with different gene networks impacting cancer development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Splicing Factor 3B subunit 1 (SF3B1) is a key component of the SF3b complex, crucial for pre-mRNA splicing.
  • Somatic SF3B1 mutations are implicated in aberrant splicing, leading to abnormal transcripts that drive cancer development and influence prognosis.

Purpose of the Study:

  • To investigate the relationship between SF3B1 and four cancer types: myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and breast cancer (BC).
  • To analyze the evolution of SF3B1's connection to these cancers from 2007 to 2018 using literature mining.

Main Methods:

  • Literature search on PubMed for articles linking SF3B1 to MDS, AML, CLL, and BC between 2007-2018.
  • Utilized publicly available databases to retrieve gene, variant, and disease information related to SF3B1.
  • Derived and analyzed complex networks to visualize correlations between SF3B1 variants and the studied cancers.

Main Results:

  • SF3B1 demonstrates a stronger association with hematologic malignancies (MDS, AML, CLL) compared to breast cancer (BC).
  • Identified that distinct gene networks may be necessary for understanding the impact of mutant splicing factors, varying by cancer type.
  • Summarized genes and cellular pathways affected by aberrant splicing in cancer cells, based on the analyzed literature.

Conclusions:

  • SF3B1 plays a significant role in hematologic malignancies, suggesting targeted therapeutic strategies.
  • The impact of SF3B1 mutations on cancer development is context-dependent, requiring cancer-type specific network analysis.
  • Aberrant splicing driven by SF3B1 mutations affects specific genes and pathways crucial for cancer cell biology.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
What is Cancer?02:12

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
10.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
408
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K